Literature DB >> 30776549

Serotyping and antimicrobial resistance of Mannheimia haemolytica strains from European cattle with bovine respiratory disease.

Sara Andrés-Lasheras1, Rahat Zaheer1, Cassidy Klima1, Haley Sanderson1, Rodrigo Ortega Polo1, Mohammad Reza Marami Milani1, Geert Vertenten2, Tim A McAllister3.   

Abstract

The objective of this study was to assess the prevalence of three serotypes, A1, A2, and A6 in 98 M. haemolytica isolates collected from clinical BRD cases in European cattle and assess their antimicrobial resistance profiles. Isolates were characterized by serotyping (plate agglutination and serotype specific PCR) and antimicrobial susceptibility testing. The study identified a predominance of serotypes A1 (59%) and A6 (22%) in European M. haemolytica isolates exhibiting a relatively low level of antimicrobial resistance. A comprehensive understanding of the relative prevalence of different M. haemolytica serotypes in Europe informs a targeted approach for vaccine design against BRD. Crown
Copyright © 2019. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antimicrobial resistance; Bovine respiratory disease; Europe; Mannheimia haemolytica; Serotyping; Vaccine

Mesh:

Substances:

Year:  2019        PMID: 30776549     DOI: 10.1016/j.rvsc.2018.12.021

Source DB:  PubMed          Journal:  Res Vet Sci        ISSN: 0034-5288            Impact factor:   2.534


  2 in total

1.  Prevalence and antibiotic susceptibility of Mannheimia haemolytica and Pasteurella multocida isolated from ovine respiratory infection: A study from Karnataka, Southern India.

Authors:  Swati Sahay; Krithiga Natesan; Awadhesh Prajapati; Triveni Kalleshmurthy; Bibek Ranjan Shome; Habibur Rahman; Rajeswari Shome
Journal:  Vet World       Date:  2020-09-23

2.  Mannheimia haemolytica serovars associated with respiratory disease in cattle in Great Britain.

Authors:  Colin Mason; Jane Errington; Geoffrey Foster; Jennifer Thacker; Oliver Grace; Katharine Baxter-Smith
Journal:  BMC Vet Res       Date:  2022-01-03       Impact factor: 2.741

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.